Oncology
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Japanese drugmaker Takeda reported a rise in revenue at the end of Japan’s financial year, but saw a significant drop in its profits. 11 May 2022
Biotechnology
The market for T-cell lymphomas (TCLs) – a rare type of the blood cancer group of non-Hodgkin’s lymphomas – is expected to see strong growth at a 6.4% compound annual growth rate (CAGR) over the next decade in the world’s eight major markets (8MM). 11 May 2022
Biotechnology
US start-up biotech MOMA Therapeutics, which is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. 10 May 2022
Pharmaceutical
German pharma major Bayer has reported a strong start to the year, with group sales up 14.3% at 14.6 billion euros ($15.4 billion), including 4.6 billion euros from pharmaceuticals, a 5.9% increase. 10 May 2022
Biotechnology
Switzerland-based Myovant Sciences and Accord Healthcare have entered into an exclusive license agreement. 9 May 2022
Biotechnology
Swiss antibody-drug conjugate specialist ADC Therapeutics today announced that Chris Martin has stepped down as chief executive of the company. 9 May 2022
Biotechnology
The year 2021 was important for the development of new gene-, cell- and tissue-based therapies, and the Alliance for Regenerative Medicines (ARM) says this year will be another year of growth and progress for these advanced therapies, according to its 2021 annual report. 9 May 2022
Biotechnology
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced progress in the Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT), an industry-led research alliance founded in 2018. 9 May 2022
Pharmaceutical
The Food and Drug Administration has announced that it is withdrawing approval of the peripheral T-cell lymphoma (PTCL) indication for Istodax (romidepsin) for injection, approved under new drug application (NDA) 022393, held by Celgene, which was acquired in 2019 by Bristol Myers Squibb for $74 billion. 7 May 2022
Biotechnology
Sino-American biotech BeiGene has announced that the China National Medical Products Administration (NMPA) has granted conditional approval of Blincyto (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). 6 May 2022
Biotechnology
Citing “an abundance of caution,” Novartis has paused production of its cancer med Luthera (lutetium Lu 177 dotatate), as well as newly-approved prostate cancer therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan). 6 May 2022
Biotechnology
In a striking vote of confidence from big pharma, British targeted protein degradation (TPD) specialist Amphista Therapeutics has inked two strategic collaborations with major drug developers. 5 May 2022
Biotechnology
The antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been approved in the USA, for the treatment of certain adults with unresectable or metastatic HER2-positive breast cancer. 5 May 2022
Biotechnology
Privately-held Dutch biotech Byondis has entered into a license and collaboration and a supply agreement with medac GmbH, a privately owned pharmaceutical company based in Germany. 5 May 2022
Biotechnology
Swiss pharma giant Novartis says that the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. 5 May 2022
Biotechnology
Tubulis, a Munich-based biotech company in the antibody drug conjugate (ADC) space, has announced the successful closing of a 60 million euros ($63 million) series B financing round. 4 May 2022
Pharmaceutical
At the annual breast cancer congress of the European Society of Medical Oncology (ESMO), Swiss pharma giant Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib). 4 May 2022
Biotechnology
Singapore-based Juniper Biologics and privately-held Swiss drugmaker Helsinn Group have signed an exclusive license agreement to develop and commercialize infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa . 4 May 2022
Biotechnology
The European Commission (EC) has approved the use of Cabometyx (cabozantinib) as a monotherapy for adults with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy. 3 May 2022
Pharmaceutical
An in-depth look at the French drugmaker's movements on the deal-making front. 3 May 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze